GLEN ALLEN, Va. & DUBLIN--(BUSINESS WIRE)--Osteologix, Inc. (“Osteologix” or the “Company”) announced that its Board of Directors has determined that the expense and management attention required for Securities and Exchange Commission (“SEC”) compliance and reporting outweigh the benefits for the Company and its shareholders in light of the history of the low trading volume of the Company’s common stock on the Over-The-Counter Bulletin Board and the resulting very limited liquidity in shares of the Company’s common stock. The Company is seeking to minimize its corporate overhead expense, while focusing its business activities on maximizing the value of the Company’s licensing agreement with the Servier Research Group and continuing to seek development partners for its strontium malonate U.S. drug development program.
